SIGNAL CONVERTER PROTEINS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 451

20. Zhang H, Su X, Liu D, Liu W, Yang P, Wang Z, et al. (1999)
Induction of specific T cell tolerance by Fas ligand-express-
ing antigen-presenting cells. J. Immunol. 162, 1423-1430.
21. Lu L, Qian S, Hershberger PA, Rudert WA, Lynch DH,
Thomson AW. (1997) Fas ligand (CD95L) and B7 expression
on dendritic cells provide counter-regulatory signals for T cell
survival and proliferation. J. Immunol. 158, 5676-5684.
22. George JF, Sweeney SD, Kirklin JK, Simpson EM, Goldstein
DR, Thomas JM. (1998) An essential role for Fas ligand in
transplantation tolerance induced by donor bone marrow.
Nat. Med. 4, 333-335.
23. Hambor JE, Weber MC, Tykocinski ML, Kaplan DR. (1990)
Regulation of allogeneic responses by expression of CD8
alpha chain on stimulator cells. Int. Immunol. 2, 879-883.
24. Tykocinski ML, Shu HK, Ayers DJ, Walter EI, Getty RR,
Groger RK, et al. (1988) Glycolipid reanchoring of
T-lymphocyte surface antigen CD8 using the 3' end sequence
of decay-accelerating factor's mRNA. Proc. Natl. Acad. Sci.
USA 85, 3555-3559.
25. Caras IW, Weddell GN, Davitz MA, Nussenzweig V, Martin
JDW. (1987) Signal for attachment of a phopholipidmembrane
anchor in decay accelerating factor. Science 238, 1280-1283.
26. Weber MC, Groger RK, Tykocinski ML. (1994) A
glycosylphosphatidylinositol-anchored cytokine can func-
tion as an artificial cellular adhesin. Exp. Cell Res. 145,
1646-1652.
27. Huang JH, Greenspan NS, Tykocinski ML. (1994) Alloanti-
genic recognition of artificial glycosyl phosphatidylinositol-
anchored HLA-A2.1. Mol. Immunol. 31, 1017-1028.
28. Brunschwig EB, Fayen JD, Medof ME, Tykocinski ML.
(1999) Protein transfer of glycosyl-phosphatidylinositol
(GPI)-modified murine B7-1 and B7-2 costimulators.
J. Immunotherapy 22, 390-400.
29. Geho DH, Fayen JD, Jackman RM, Moody BD, Porcelli SA,
Tykocinski ML. (2000) Glycosyl-phosphastidylinositol rean-
choring unmasks distinct antigen-presenting pathways for
CD1b and CD1c. J. Immunol. 65, 1272-1277.
30. Medof ME, Nagarajan S, Tykocinski ML. (1996) Cell surface
engineering with GPI-anchored proteins. FASEB J. 10,
574-586.
31. Fayen JD, Tykocinski ML, Medof ME. (2000) Glycerolphos-
phoinositide anchors for membrane-tethering proteins.
Methods Enzymol. 327, 351-368.
32. De Bruijn MLH, Schumacher TNM, Nieland JD, Ploegh HL,
Kast WM, Melief CJM. (1991) Peptide loading of empty
major histocompatibility complex molecules on RMA-S cells
allows the induction of primary cytotoxic T lymphocyte
responses. Eur. J. Immunol. 21, 2963-2970.
33. McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P.
(1995) Construction, purification, and functional incorpora-
tion on tumor cells of glycolipid-anchored human B7-1
(CD80). Proc. Natl. Acad. Sci. USA 92, 8059-8063.
34. Brunschwig EB, Levine E, Trefzer U, Tykocinski ML.
(1995) Glycosylphosphatidylinositol-modified murine B7-1
and B7-2 retain costimulator function. J. Immunol. 155,
5498-5505.

35. Chen A, Zheng G, Tykocinski ML. (2000) Hierarchical
costimulator thresholds for distinct immune responses: appli-
cation of a novel two-step fc fusion protein transfer method.
J. Immunol. 164, 705-711.
36. Zheng G, Chen A, Sterner RE, Zhang PJ, Pan T, Kiyatkin N,
et al. (2001) Induction of antitumor immunity via intratu-
moral tetra-costimulator protein transfer. Cancer Res. 61,
8127-8134.
37. Huang JH Tykocinski ML. (2001) CTLA-4-fas ligand func-
tions as a trans signal converter protein in bridging antigen-
presenting cells and T cells. Int. Immunol. 13, 529-539.
38. Rudd CE, Taylor A, Schneider H. (2009) CD28 and CTLA-4
coreceptor expression and signal transduction. Immunol. Rev.
229, 12-26.
39. Noel PJ, Boise LH, Green JM, Thompson CB. (1996) CD28
costimulation prevents cell death during primary T cell
activation. J. Immunol. 157, 636-642.
40. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB.
(1999) Blocking both signal 1 and signal 2 of T-cell activation
prevents apoptosis of alloreactive T cells and induction of
peripheral allograft tolerance. Nat. Med. 5, 1298-1302.
41. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S,
Gaide O, Martinon F, et al. (2003) Two adjacent trimeric Fas
ligands are required for Fas signaling and formation of a death-
inducing signaling complex. Mol. Cell. Biol. 23, 1428-1440.
42. Schneider P, Tschopp J. (2000) Apoptosis induced by death
receptors. Pharm. Acta Helv. 74, 281-286.
43. Schmidt EM, Wang CJ, Ryan GA, Clough LE, Qureshi OS,
Goodall M, et al. (2009) Ctla-4 controls regulatory T cell
peripheral homeostasis and is required for suppression of
pancreatic islet autoimmunity. J. Immunol. 182, 274-282.
44. Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J,
Zhang Y, et al. (2009) CD4 þ regulatory T cells require
CTLA-4 for the maintenance of systemic tolerance.

J. Exp. Med. 206, 421-434.
45. Baban B, Hansen AM, Chandler PR, Manlapat A, Bingaman
A, Kahler DJ, et al. (2005) A minor population of splenic
dendritic cells expressing CD19 mediates IDO-dependent T
cell suppression via type I IFN signaling following B7
ligation. Int. Immunol. 17, 909-919.
46. Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka
LA. (1999) The role of CD80, CD86, and CTLA4 in alloim-
mune responses and the induction of long-term allograft
survival. J. Immunol. 162, 1947-1951.
47. Koenen HJ, Joosten I. (2000) Blockade of CD86 and CD40
induces alloantigen-specific immunoregulatory T cells that
remain anergic even after reversal of hyporesponsiveness.
Blood 95, 3153-3161.
48. Wallace PM, Rodgers JN, Leytze GM, Johnson JS, Linsley
PS. (1995) Induction and reversal of long-lived specific
unresponsiveness to a T-dependent antigen following
CTLA4Ig treatment. J. Immunol. 154, 5885-5895.
49. Newell KA, He G, Guo Z, Kim O, Szot GL, Rulifson I, et al.
(1999) Cutting edge: blockade of the CD28/B7 costimulatory
pathway inhibits intestinal allograft rejection mediated by
CD4 þ but not CD8 þ T cells. J. Immunol. 163, 2358-62.